Pfizer is adding follow-on biologics to pipeline

04/27/2010 | Wall Street Journal, The

Pfizer is working to boost its biotech business by developing new versions of blockbuster treatments, including formulations of blood cancer drug Rituxan and rheumatoid arthritis medicine Enbrel that require fewer injections. The company is using Trubion Pharmaceuticals' technology to tailor the "bio-betters," some of which are in midstage development.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC